Drug Trial Radar · NCT03731260
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
251
Actual
Start
Apr 16, 2019
Primary completion
Jun 23, 2027
Study completion Jun 23, 2027
Sponsor
- Lead sponsor
- Blueprint Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Nov 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The study will be conducted in 3 parts. All patients will receive treatment with avapritinib during Part 3 including those rolling over from the placebo group.
Conditions
- Indolent Systemic Mastocytosis
Interventions
AvapritinibDrug
Avapritinib tablet
PlaceboDrug
Placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Recommended Phase 2 dose (RP2D) in patients with ISMTime frame: 9 months
- Part 2: Mean change in ISM Symptom Assessment Form (ISM-SAF) total symptom score (TSS) as compared to placeboTime frame: 6 months
- Part 3: Number of Participants with Adverse EventsTime frame: Up to 5 years
Locations
49 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic Hospital
Phoenix, Arizona
Stanford Cancer Institute
Stanford, California
Mayo Clinic Florida
Jacksonville, Florida
H. Lee Moffitt Cancer Center
Tampa, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
University of Kansas Hospital
Kansas City, Kansas
Brigham & Women's Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Michigan Medicine, University of Michigan
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Herbert Irving Comprehensive Cancer Center
New York, New York
Duke University Health System (DUHS)
Durham, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
University of Texas, MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Commonwealth University Medical Center
Richmond, Virginia
University Hospital Antwerp
Edegem, Belgium
Tom Baker Cancer Centre
Calgary, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Odense Universitetshospital, ORCA/Allergicentret, Hudafdeling I og Allergicenter
Odense, Denmark
Hôpital de la Timone, Service de dermatologie
Marseille, France
Hôpital Pitié-Salpêtrière, Service de Dermatologie
Paris, France
CHU Toulouse Larrey, CEREMAST, Service de Dermatologie et Allergologie cutanée
Toulouse, France
Uniklinik RWTH Aachen
Aachen, Germany
Charité Universitätsmedizin Berlin
Berlin, Germany
University Clinic Hamburg Eppendorf, University Cancer Center Hamburg (UCCH)
Hamburg, Germany
Universitätsklinikum Schleswig-Holstein, Hämatologie/Onkologie
Lübeck, Germany
Universitätsklinik Mainz, Universitäts-Hautklinik, Clinical Research Center
Mainz, Germany
Universitätsmedizin Mannheim, III. Medizinische Klinik
Mannheim, Germany
Klinikum rechts der Isar, Technische Universität München
Munich, Germany
A.O.U di Bologna - IRCCS, Istituto di Ematologia Lorenzo e Ariosto Seragnoli, Ematologia
Bologna, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Poloclinico, UOC Ematologia
Milan, Italy
A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno
Salerno, Italy
Azienda Ospedaliera Universitaria Integrata di Verona
Verona, Italy
University Medical Center Groningen (UMCG)
Groningen, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.